PsyBio Therapeutics (“PsyBio”) is a biotechnology company developing a portfolio of psychoactive compounds targeted for the treatment of mental health challenges and other disorders.
The Company has a collaboration with Miami University, Oxford Ohio where they have filed intellectual property for biosynthesized psilocybin, it’s intermediates, and other molecules.
With a proprietary platform technology, the Company is in the process of developing new drugs by producing novel psychoactive molecules from genetically modified bacteria. The platform is expected to enable the rapid generation of highly stable compounds far cheaper, faster and greener than any other published method.
Currently working in the laboratory on over twenty psychedelically inspired compounds from different fungi and plants with unique psychoactive properties.
PsyBio is in the process of preparing the initial molecules for clinical batch manufacturing and concurrently preparing an investigational new drug (“IND”) application to study the compounds in patients with cancer related depression.